Daily Endocrinology Research Analysis
Analyzed 73 papers and selected 3 impactful papers.
Summary
Three high-impact studies advanced endocrine-related science and clinical practice. A multi-ancestry GWAS meta-analysis uncovered new maternal genetic loci for gestational diabetes and pregnancy glycaemia, largely overlapping with type 2 diabetes biology but with pregnancy-amplified effects. An IPD meta-analysis refined cervical length prognostication for spontaneous preterm birth with a clear non-linear risk curve, while a thyroid oncology cohort showed that thyroglobulin antibody classification using assay LOQ improves recurrence risk stratification when thyroglobulin is undetectable.
Research Themes
- Pregnancy-specific genetics and glycemic regulation
- Non-linear risk modeling in obstetric prognostics
- Assay-informed biomarkers improving thyroid cancer surveillance
Selected Articles
1. Multi-ancestry, trans-generational GWAS meta-analysis of gestational diabetes and glycaemic traits during pregnancy reveals limited evidence of pregnancy-specific genetic effects.
This multi-ancestry GWAS meta-analysis (≈814,450 participants) identified 37 loci for gestational diabetes (7 novel) and five novel loci for pregnancy glycaemic traits, acting through the maternal genome. While overlapping broadly with type 2 diabetes biology, several loci showed pregnancy-amplified or distinct effects, refining etiologic understanding and risk stratification opportunities.
Impact: It delivers large-scale, ancestry-spanning genetic insights into GDM, revealing novel and pregnancy-modified loci that bridge and differentiate GDM from T2DM biology.
Clinical Implications: Findings support development of maternal genetic risk scores for GDM, inform postpartum T2D risk, and prioritize loci (e.g., MTNR1B, GCK, HKDC1) for mechanistic and therapeutic exploration in pregnancy.
Key Findings
- Identified 37 GDM-associated loci (7 novel) and five novel loci for pregnancy glycaemic traits across up to 814,450 participants.
- All detected effects operated through the maternal genome; several variants had stronger effects in GDM than T2D.
- Four loci (G6PC2, CAST-PCSK1, HKDC1, FOXA2) lacked genome-wide-significant T2D associations; GCK showed distinct causal variants; MTNR1B exhibited pregnancy-amplified effects.
Methodological Strengths
- Trans-generational, multi-ancestry GWAS meta-analysis with very large sample size.
- Systematic classification of GDM variants to disentangle pleiotropy and pregnancy-modified effects.
Limitations
- Despite breadth, larger ancestrally diverse cohorts are needed to resolve pregnancy-specific effects.
- Genetic association cannot establish mechanism; diagnostic heterogeneity across cohorts may influence effect estimates.
Future Directions: Expand ancestrally diverse maternal-fetal triad analyses, integrate polygenic risk with clinical predictors, and perform mechanistic studies of prioritized loci in pregnancy.
Gestational diabetes mellitus (GDM) affects ~14% of pregnancies and increases maternal type 2 diabetes mellitus (T2DM) risk. The GenDiP Consortium presents trans-generational, multi-ancestry genome-wide association study meta-analyses of GDM and pregnancy glycemic traits in up to 38,305 GDM cases and 776,145 controls. We identify 37 GDM-associated loci (7 novel) and five novel loci for pregnancy glycemic traits, all operating through the maternal genome. We classify 12 GDM variants with stronger effects in GDM than T2DM into five biologically informed categories, revealing pleiotropy patterns, pregnancy-dependent effect modification, and diagnostic heterogeneity. While all these loci overlap with T2DM and/or non-pregnant glycaemic traits, four (G6PC2, CAST-PCSK1, HKDC1, FOXA2) lack genome-wide-significant T2DM associations; GCK shows distinct causal variants for GDM, and MTNR1B exhibits pregnancy-amplified effects. Our findings provide new genetic insights into GDM and highlight the need for larger, ancestrally diverse studies of GDM and glycaemic traits during pregnancy to understand potential pregnancy-specific effects.
2. Prognostic value of cervical length for spontaneous preterm birth in asymptomatic women with singleton pregnancy: An individual participant data meta-analysis.
In an IPD meta-analysis of 27 studies (n=91,404), cervical length at ~20 weeks showed an L-shaped relationship with spontaneous preterm birth, with risk decreasing steeply up to 40 mm and stabilizing beyond. Compared to 40 mm, 20 mm and 30 mm were associated with 6.22- and 2.10-fold higher odds of SPTB, informing risk communication and thresholding.
Impact: Provides high-quality, IPD-based, non-linear risk modeling for a widely used obstetric predictor, refining clinical thresholds and counseling.
Clinical Implications: Supports nuanced interpretation of cervical length: risk is progressively higher below 40 mm and stable above, guiding surveillance intensity and preventive interventions (e.g., progesterone, cerclage) in asymptomatic singleton pregnancies.
Key Findings
- Across 91,404 participants, SPTB <37 weeks occurred in 5.2% and cervical length averaged 40 mm at ~20 weeks.
- An L-shaped non-linear association: odds of SPTB fell steeply up to 40 mm and plateaued beyond.
- Relative to 40 mm, cervical lengths of 20 mm and 30 mm had 6.22 and 2.10 higher odds of SPTB, respectively.
Methodological Strengths
- Prospectively registered IPD meta-analysis with QUIPS-based bias assessment.
- Two-stage modeling using restricted cubic splines to capture non-linear effects.
Limitations
- IPD retrieval covered 51% of eligible participants, raising potential selection bias.
- Limited availability of harmonized co-predictors across datasets.
Future Directions: Standardize co-predictor collection and validate clinical decision thresholds in prospective studies of preventive interventions triggered by cervical length.
BACKGROUND: Spontaneous preterm birth (SPTB) is the leading cause of perinatal and early childhood mortality worldwide. Studies have generally suggested that mid-trimester transvaginal sonographic cervical length <25 mm is an important predictor of SPTB. Aggregate data meta-analyses are limited by data availability and reporting in the primary literature. The purpose of this individual participant data meta-analysis (IPDMA) was to quantify the prognostic value of mid-trimester cervical length for SPTB in asymptomatic women with singleton pregnancy, and to assess other factors which may modify this association. METHODS AND FINDINGS: The project was prospectively registered with PROSPERO (CRD42020146987). We searched Medline, Embase, CINAHL, LILACS, Database of Abstracts of Reviews of Effects (DARE), Cochrane database, JBI Database of Systematic Reviews, ClinicalTrials.gov, and Google Scholar. We included cohort studies and non-treatment arms of randomized controlled trials which assessed an association between mid-trimester transvaginal sonographic cervical length and SPTB in asymptomatic women with singleton pregnancy. The search was performed on 30/9/2020, with an update performed on 4/11/2025. The primary outcome was STPB <37 weeks. Two reviewers screened all studies for inclusion and performed risk of bias assessments using QUIPS. We performed a two-stage IPDMA in a logistic regression model using cervical length as a continuous variable (the primary analysis) with restricted cubic splines to explore non-linear associations. IPD of 27 eligible studies were obtained and included (n = 91,404). Mean cervical length was 40 mm (standard deviation [SD] 9 mm) at about 20 weeks' gestation. SPTB <37 weeks occurred in 4,442 (5.2%) participants. An L-shape non-linear association between cervical length and SPTB was observed. A longer cervical length was associated with steeply lower odds of SPTB until it reached 40 mm, beyond which the odds of SPTB became stable. This means that compared to a woman with a cervical length of 40 mm, those with a cervical length of 20 and 30 mm were associated 6.22 and 2.10 higher odds of SPTB (95% confidence intervals [4.76, 8.13] and [1.85, 2.38]), respectively. Limitations included suboptimal data retrieval rate (51% of all eligible participants) and a lack of comprehensive co-predictors of SPTB across all datasets. CONCLUSION: We found a non-linear association between cervical length and SPTB. We found a non-linear association between cervical length and SPTB. Shorter cervix is associated with progressively higher risk of SPTB when length is less than 40 mm, but probability of term birth is high when cervical length is over 40 mm.
3. Prognostic Significance of Detectable Antithyroglobulin Antibodies Based on Analytical Sensitivity in Papillary Thyroid Carcinoma with Undetectable Serum Thyroglobulin after Radioactive Iodine Treatment.
In 1,039 PTC patients with undetectable Tg 6–12 months post-RAI, classifying TgAb by assay LOQ (43.4 U/mL) improved prognostication: 10-year PFS was 97.9% (undetectable), 94.6% (borderline), and 88.5% (elevated). LOQ-based TgAb positivity identified higher recurrence risk despite undetectable Tg.
Impact: Introduces an analytically grounded TgAb threshold that enhances recurrence risk stratification when Tg is undetectable, directly informing surveillance strategies.
Clinical Implications: Adopting LOQ-based TgAb classification can refine risk-adapted surveillance and imaging in Tg-undetectable PTC survivors, potentially reducing missed recurrences and unnecessary testing.
Key Findings
- Among 1,039 PTC patients with undetectable Tg post-RAI, TgAb stratified by LOQ (43.4 U/mL) identified differential 10-year PFS (97.9% vs 94.6% vs 88.5%).
- LOQ-based TgAb positivity was associated with higher recurrence risk despite undetectable Tg.
- LOQ classification may outperform conventional reference limits (60 U/mL) for prognostic assessment.
Methodological Strengths
- Large single-disease cohort (n=1,039) with long median follow-up (12 years).
- Analytically informed thresholding using assay-specific LOQ.
Limitations
- Retrospective design; generalizability may depend on assay platform and single-center protocols.
- External validation across assays and centers is required to confirm thresholds and cut-points.
Future Directions: Prospective, multi-center validation of LOQ-based TgAb thresholds across platforms and integration into dynamic risk stratification algorithms.
BACKGROUND: Serum thyroglobulin (Tg) is a key tumor marker in papillary thyroid carcinoma (PTC), but its reliability may be compromised by the presence of antithyroglobulin antibodies (TgAb). Utilizing the assay-specific limit of quantification (LOQ) may enhance the detection of TgAb-related interference compared with the traditional reference limit. This study evaluated postoperative TgAb levels based on LOQ as a surrogate marker for tumor monitoring in PTC. METHODS: A total of 1039 patients with PTC (≥1 cm) who had undetectable unstimulated serum Tg (<0.2 ng/mL) 6-12 months after total thyroidectomy with radioactive iodine (RAI) ablation therapy (2009-2012) were retrospectively analyzed. Simultaneously measured TgAb levels were classified using both the reference limit (60.0 U/mL) and LOQ (43.4 U/mL) into three groups undetectable (<43.4 U/mL), borderline (43.4-60.0 U/mL), and elevated (>60.0 U/mL). RESULTS: The median age was 48.2 years, and 188 (18.1%) were male. The median tumor size was 1.5 cm, and lymph node metastases were present in 705 patients (67.8%). During a median follow-up of 12.0 years, recurrence occurred in 4.8%. Based on initial TgAb level, patients were classified as undetectable (65.6%), borderline (23.5%), and elevated (10.9%), with corresponding 10-year progression-free survival rates of 97.9%, 94.6%, and 88.5%, respectively ( CONCLUSIONS: TgAb levels above the LOQ were associated with a higher recurrence risk in patients with PTC with undetectable Tg after RAI treatment. Classification of TgAb positivity based on the LOQ may improve prognostic assessment compared with evaluation using conventional reference limits. Further studies are needed to validate our findings and refine TgAb thresholds.